Start Submission Become a Reviewer

Reading: Impacting Global Health Delivery Through Advocacy: The Case of Losartan

Download

A- A+
Alt. Display

Letter to the Editor

Impacting Global Health Delivery Through Advocacy: The Case of Losartan

Authors:

David J. Heller ,

Arnhold Institute for Global Health, Icahn School of Medicine at Mount Sinai, New York, NY, US
X close

Sandeep P. Kishore

Arnhold Institute for Global Health, Icahn School of Medicine at Mount Sinai, New York, NY, US
X close

Abstract

Highlights

  • The WHO’s EML improves medicine access.
  • Anyone can lobby to add a medicine to the EML, so we added losartan in 2017.
  • Evidence now shows losartan is more impactful than previously realized.
  • You too can use the EML to effect policy change—by adding to or amending it.
  • Also, you can hold governments accountable to keep EML medicines on their shelves.
How to Cite: Heller DJ, Kishore SP. Impacting Global Health Delivery Through Advocacy: The Case of Losartan. Global Heart. 2019;14(1):95–6. DOI: http://doi.org/10.1016/j.gheart.2018.11.001
7
Views
6
Downloads
Published on 01 Mar 2019.

Downloads

  • PDF (EN)

    comments powered by Disqus